Dietrich John Pauls

CIK: 0001760123

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

DMAC

DiaMedica Therapeutics Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

DMAC
DiaMedica Therapeutics Inc.
Aug 10, 2026
Award(A)
Direct
60.2K shares-
DMAC
DiaMedica Therapeutics Inc.
Jun 1, 2026
Award(A)
Stock Option (right to buy)
Direct
380K shares-
DMAC
DiaMedica Therapeutics Inc.
Jun 1, 2025
Award(A)
Stock Option (right to buy)
Direct
600K shares-

		Type	Shares	Price		Ownership
Aug 10, 2026	DMAC DiaMedica Therapeutics Inc.	Award(A)	60,200	-	$0	Direct
Jun 1, 2026	DMAC DiaMedica Therapeutics Inc.	Award(A) Stock Option (right to buy)	380,000	-	-	Direct
Jun 1, 2025	DMAC DiaMedica Therapeutics Inc.	Award(A) Stock Option (right to buy)	600,000	-	-	Direct

1-3 of 3 transactions

About Pauls Dietrich John

Pauls Dietrich John (SEC CIK 0001760123) files insider reports with the SEC as President & CEO of DiaMedica Therapeutics Inc. (DMAC).

Signal8 holds 3 ownership filings by Pauls Dietrich John, all Form 4s, filed between Jun 3, 2025 and Aug 12, 2026. Those filings report 3 transactions, from Jun 1, 2025 to Aug 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Pauls Dietrich John's filings is in MINNEAPOLIS, MN.

Recent filings by Pauls Dietrich John

Aug 10, 2026: Grant or award of DMAC shares (Form 4, code A).
Jun 1, 2026: Grant or award of DMAC derivative securities (Form 4, code A).
Jun 1, 2025: Grant or award of DMAC derivative securities (Form 4, code A).

Other insiders filing for DiaMedica Therapeutics Inc. (DMAC)

How to read Form 4 transaction codes